A second-generation blood substitute (perfluorodichlorooctane emulsion) does not activate complement during an ex vivo circulation model of bypass

J Cardiothorac Vasc Anesth. 1998 Aug;12(4):397-401. doi: 10.1016/s1053-0770(98)90191-4.

Abstract

Objectives: To examine whether a second-generation perfluorocarbon (PFC) blood substitute added to the cardiopulmonary bypass (CPB) prime influences complement production.

Design: A prospective, randomized, single-blinded, ex vivo model.

Setting: A university hospital, laboratory, and clinics.

Participants: Ten healthy adult consented volunteer blood donors (five men, five women).

Interventions: Ex vivo closed-loop extracorporeal circuit including membrane oxygenator, tubing, and filter primed with crystalloid or crystalloid plus PFC was circulated for 1 hour with the addition of 500 mL of heparinized fresh human whole blood.

Measurements and main results: Laboratory specimens were drawn from the circuit at 10-minute intervals for 1 hour and measured for complement (C3a, Bb fragment) concentrations, blood gases, fibrinogen concentration, platelet count, and hematocrit. In the PFC group, C3a and Bb fragments were equal to or less than those in the group that received crystalloid alone.

Conclusion: The second-generation PFC added to the prime of a CPB circuit does not independently increase complement production.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Anticoagulants / therapeutic use
  • Blood Substitutes / administration & dosage
  • Blood Substitutes / therapeutic use*
  • Cardiopulmonary Bypass* / instrumentation
  • Cardiopulmonary Bypass* / methods
  • Complement Activation / drug effects*
  • Complement C3a / analysis
  • Complement C3a / biosynthesis
  • Complement Factor B / analysis
  • Complement Factor B / biosynthesis
  • Crystalloid Solutions
  • Emulsions
  • Female
  • Filtration / instrumentation
  • Fluorocarbons / administration & dosage
  • Fluorocarbons / therapeutic use*
  • Heparin / therapeutic use
  • Humans
  • Hydrocarbons, Chlorinated / administration & dosage
  • Hydrocarbons, Chlorinated / therapeutic use*
  • Hydrocarbons, Fluorinated / administration & dosage
  • Hydrocarbons, Fluorinated / therapeutic use*
  • Isotonic Solutions
  • Male
  • Middle Aged
  • Oxygenators, Membrane
  • Plasma Substitutes / therapeutic use
  • Prospective Studies
  • Single-Blind Method

Substances

  • Anticoagulants
  • Blood Substitutes
  • Crystalloid Solutions
  • Emulsions
  • Fluorocarbons
  • Hydrocarbons, Chlorinated
  • Hydrocarbons, Fluorinated
  • Isotonic Solutions
  • Plasma Substitutes
  • perfluorodichlorooctane
  • Complement C3a
  • Heparin
  • Complement Factor B